Abstract
Carefully conducted and appropriately reported clinical trials are of fundamental importance in evidence-based medicine. This applies to both new and established treatments (see, for example, p291–2 of this issue). It is estimated that about half of all clinical trials are not reported; this is a problem of which we have been aware since 1986, if not earlier. Perhaps unsurprisingly, there is a bias to the publication of ‘positive’ trials. The selective reporting of trials to regulatory agencies and in the medical literature influences decisions about the licensing and use of pharmaceutical agents in clinical practice.
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callSimilar Papers
More From: The journal of the Royal College of Physicians of Edinburgh
Disclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
